<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    St Renatus LLC

    St. Renatus, LLC, named after the patron saint of anesthesia, is a privately held ...

    St. Renatus, LLC, named after the patron saint ...

    Filing Type:    RA
    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...

    Cyclerion Therapeutics is a clinical-stage biop...

    Filing Type:    PU
    GenMark Diagnostics, Inc.

    GenMark Diagnostics, Inc.

    GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...

    GenMark Diagnostics (NASDAQ: GNMK) is a leading...

    Filing Type:    PU
    Anixa Biosciences, Inc.

    Anixa Biosciences, Inc.

    Anixa is focused on harnessing the body’s immune system in the fight against can...

    Anixa is focused on harnessing the body’s imm...

    Filing Type:    PU
    United Therapeutics Corporation

    United Therapeutics Corporation

    United Therapeutics Corporation focuses on the strength of a balanced, value-creat...

    United Therapeutics Corporation focuses on the ...

    Filing Type:    PU
    Celldex Therapeutics, Inc.

    Celldex Therapeutics, Inc.

    Celldex is developing targeted therapeutics to address devastating diseases for wh...

    Celldex is developing targeted therapeutics to ...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Jounce Therapeutics, Inc.

    Jounce Therapeutics, Inc.

    Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...

    Jounce Therapeutics is a clinical stage immunot...

    Filing Type:    PU
    Enochian Biosciences, Inc.

    Enochian Biosciences, Inc.

    Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...

    Enochian Biosciences is a pre-clinical stage bi...

    Filing Type:    PU
    Gilead Sciences, Inc.

    Gilead Sciences, Inc.

    Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers...

    Gilead Sciences, Inc. is a research-based bioph...

    Filing Type:    PU
    Scholar Rock Holding Corporation

    Scholar Rock Holding Corporation

    Scholar Rock is a biopharmaceutical company focused on the discovery and developme...

    Scholar Rock is a biopharmaceutical company foc...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.